Table 3. Grade 2–5 toxicity by maximum grade per patient (N=17)a.
|
DL 4, 5A, 5B (n=17)
|
Ovarian cancer (n=19, all DLs)
|
|||||
|---|---|---|---|---|---|---|
|
Maximum toxicity grade (no. of patients)
|
Maximum toxicity grade (no. of patients)
|
|||||
| G2 | G3 | G4 | G2 | G3 | G4 | |
| Diarrhoea | 2 | 2 | 0 | 2 | 1 | 0 |
| Fatigue | 2 | 1 | 0 | 4 | 2 | 0 |
| Fistula | 1 | 0 | 0 | 2 | 0 | 0 |
| Mucositisa | 3 | 2 | 0 | 0 | 0 | 0 |
| Skin rashes | ||||||
| HFSR | 8a | 0 | 0 | 17 | 0 | 0 |
| Otherb | 2 | 0 | 0 | 0 | 0 | 0 |
| Hypertension | 7 | 3 | 0 | 9 | 6 | 0 |
| Perforation | 0 | 1 | 0 | 0 | 0 | 0 |
| Proteinuria | 2 | 0 | 0 | 1 | 1 | 0 |
| Thrombocytopaenia | 0 | 0 | 0 | 0 | 1 | 0 |
| Thrombosis | 0 | 2 | 0 | 1 | 0 | 1 |
| Transaminitis | 2 | 2 | 0 | 3 | 1 | 0 |
DLs=dose levels; HFSR=hand–foot skin reaction.
a
One patient had mouth, tongue, throat. and anal mucositis.
b
Ear and perirectal desquamation and rashes.